BioSpace News Archive

Oxford Nanopore users have easy access to precise whole genome methylation detection from PCR-free nanopore sequencing using Remora.

Medical Microinstruments SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced the launch of its Symani Surgical System Simulator developed by VirtaMed.

Evox Therapeutics Ltd, a leading exosome therapeutics company, announced advances in exosome engineering, manufacturing and tissue targeting at the International Society for Extracellular Vesicles Annual Meeting, on May 25 to 29, 2022, in Lyon, France.

GenScript USA Inc., a subsidiary of GenScript Biotech Corporation, a world-leading biotechnology company, has reached an agreement with EUROIMMUN US Inc., a PerkinElmer Company, for the distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in the United States and Canada.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review of its New Drug Application for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of NX-2127, an orally administered degrader of Bruton’s tyrosine kinase (BTK) with immunomodulatory activity.

Ortho Regenerative Technologies Inc. announced today that it has received, through its partnership with Polytechnique Montreal, a $500,000 non-dilutive grant from Axelys, to advance the development of its second technology platform indication, ORTHO-M, for meniscus repair.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first quarter ended March 31, 2022.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that members of its management team will participate in two upcoming investor conferences.

ZAP Surgical’s CEO and Stanford Neurosurgeon Receives Prestigious Janeway Medal, Recognized for Pioneering and Continued Advancement of Radiosurgical Brain Tumor Therapy.